[{"id":"04b5fff0-3325-4a83-9d7a-6930c6fb5088","acronym":"","url":"https://clinicaltrials.gov/study/NCT05907759","created_at":"2023-06-18T18:08:20.498Z","updated_at":"2025-02-25T14:42:08.936Z","phase":"Phase 2","brief_title":"Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma","source_id_and_acronym":"NCT05907759","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex Faspro (daratumumab and hyaluronidase-fihj)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 07/10/2024","start_date":" 07/10/2024","primary_txt":" Primary completion: 08/01/2034","primary_completion_date":" 08/01/2034","study_txt":" Completion: 12/01/2035","study_completion_date":" 12/01/2035","last_update_posted":"2025-02-14"},{"id":"6c8187f2-a1a7-4e0d-9839-99324cab5154","acronym":"","url":"https://clinicaltrials.gov/study/NCT06022939","created_at":"2023-09-05T18:12:25.015Z","updated_at":"2024-07-02T16:34:27.373Z","phase":"Phase 3","brief_title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","source_id_and_acronym":"NCT06022939","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CD34","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 338","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 07/29/2030","primary_completion_date":" 07/29/2030","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2024-06-11"},{"id":"2dc1fa48-405c-43a2-8874-34fe5b578aec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04824794","created_at":"2022-12-14T16:58:25.975Z","updated_at":"2024-07-02T16:34:59.269Z","phase":"Phase 1/2","brief_title":"GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies","source_id_and_acronym":"NCT04824794","lead_sponsor":"Genmab","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex Faspro (daratumumab and hyaluronidase-fihj) • erzotabart (GEN3014)"],"overall_status":"Recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 03/09/2021","start_date":" 03/09/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-04"},{"id":"1fffbecc-9d1d-4405-aa75-3725ff51616b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807048","created_at":"2023-04-10T14:03:23.661Z","updated_at":"2024-07-02T16:35:07.816Z","phase":"Phase 2","brief_title":"Daratumumab in STK11 Mutated NSCLC","source_id_and_acronym":"NCT05807048","lead_sponsor":"NYU Langone Health","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex Faspro (daratumumab and hyaluronidase-fihj)"],"overall_status":"Recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-24"},{"id":"96e82999-ebea-468e-ae05-e9929f4ac0ba","acronym":"DARANIVOVAX","url":"https://clinicaltrials.gov/study/NCT06015724","created_at":"2023-08-29T16:10:12.521Z","updated_at":"2025-02-25T14:18:13.340Z","phase":"Phase 2","brief_title":"Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06015724 - DARANIVOVAX","lead_sponsor":"Georgetown University","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • STK11","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 mutation • KRAS G12","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/31/2024","start_date":" 01/31/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-02-05"},{"id":"67a15808-0681-4add-b990-145069d8cdb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04714372","created_at":"2021-01-19T20:53:07.373Z","updated_at":"2024-07-02T16:35:23.907Z","phase":"Phase 1","brief_title":"FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia","source_id_and_acronym":"NCT04714372","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • IDH1 • IDH2 • CD38","pipe":" | ","alterations":" CD38 expression","tags":["FLT3 • IDH1 • IDH2 • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT538 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 11/03/2021","start_date":" 11/03/2021","primary_txt":" Primary completion: 01/09/2024","primary_completion_date":" 01/09/2024","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2024-01-10"}]